Actinium has forged strong partnerships with companies globally who share our vision of bringing targeted radiotherapies to patients in need.
Below are our existing partnerships and collaborations including for our lead clinical program Iomab-B, which complete patient enrollment in 3Q 2021 and will report topline data in 3Q 2022 and our AWE technology platform that is being utilized in the development developing novel targeted radiotherapies for both solid tumors and blood cancers.
In April 2022, Actinium announced Immedica licensed the rights to commercialize Iomab-B (1-131 apamistamab) in the EU, Middle East and North Africa. Actinium received a $35 million upfront payment and is eligible to receive up to an additional $417 million in potential regulatory and sales milestones as well as royalties in the mid-twenty percent range of Iomab-B sales under the terms of the license agreement.
Immedica is a fast-growing private niche pharma group with headquarter in Stockholm, Sweden and commercial coverage across Europe and the Middle East. Immedica has significant know-how and experience in commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality, and product distribution.
To learn more about potential clinical collaboration opportunities please contact Arun Swaminathan, Ph.D., Actinium’s Chief Business and Commercial Officer at firstname.lastname@example.org.
In 2021, Actinium and Astellas announced a continuation of our collaborative research partnership focused on developing theranostics to both image and diagnose solid tumor cancers and treat them leveraging Actinium’s AWE technology platform to utilize the Ac-225 radioisotope warhead with select targeting agents owned by Astellas as part of its Rx+© initiative.
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. Astellas promotes its Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, it also looks beyond their foundational Rx focus to create Rx+® healthcare solutions that combine Astellas’ expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit Astellas’ website at https://www.astellas.com/en.
To learn more about potential AWE technology collaboration opportunities please contact Monideepa Roy, Ph.D., Vice President, Corporate Development – R&D at email@example.com.
In February 2022, Actinium and AVEO entered into a research collaboration to develop a first in class HER3 (ErbB3) targeting radiotherapy using the Actinium-225 radioisotope warhead for solid tumors. AVEO's HER3 targeting antibodies are designed to inhibit both ligand-dependent and ligand-independent signaling. HER3 is a receptor that is typically expressed in many human cancers and has demonstrated preclinical activity in multiple tumor models.
In January 2022, we announced a Strategic Research Collaboration with EpicentRx, Inc. to combine targeted radiotherapy with EpicentRx’s CD47-SIRPα immunotherapy RRx-001, which has been studied in Phase 3 clinical trials in lung cancer. At the Society of Immunotherapy for Cancer (SITC) meeting in November 2021 and American Association for Cancer Research (AACR) we presented the first ever data combining targeted radiotherapy with a CD47 immunotherapy, magrolimab which is being developed by Gilead Sciences, and showed that targeted radiotherapy increased cell surface calreticulin and “eat me” signal that resulted in increased phagocytosis and enhanced tumor growth inhibition. In this collaboration, we will leverage our clinical experience with targeted radiotherapies for patients with AML and will work to advance our targeted radiotherapy with RRx-001 to the clinic.